Idelalisib (Zydelig) should not be used in combination with rituximab in a range of patients with haematological malignancies, the TGA advises. The alert follows serious adverse events, including death, in patients receiving idelalisib and other cancer medicines as part of a phase 3 clinical trial which has since been discontinued. Patients with chronic lymphocytic leukaemia ...
Warning issued on blood cancer drug
20 Apr 2017